Santen and Sydnexis partner on childhood myopia treatment SYD-101
Phase III trials are ongoing in Europe and the US
Read More
Tag: myopia
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
